A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at community pharmacies. The case was one of many similar lawsuits challenging similar state law. In this case, the court dismissed a series of legal claims brought by AstraZeneca, AbbVie, Inc. and PhRMA, including preemption, vagueness, Contract Clause and Takings Clause claims. 
 
The AHA filed friend-of-the-court briefs regarding the case Feb. 29 and last December. 

Related News Articles

Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA Aug. 7 filed an amicus brief in the Supreme Court in defense of states’ affidavit of merit requirements in federal court, which require plaintiffs to…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…